These members were selected on the basis of their experience in the field to provide broad expertise in the design, conduct, and use of cost-effectiveness analyses. In 2012, the Second Panel on Cost-Effectiveness in Health and Medicine was formed and included 2 co-chairs, 13 members, and 3 additional members of a leadership group. The intended audiences include researchers, government policy makers, public health officials, health care administrators, payers, businesses, clinicians, patients, and consumers.
To review the state of the field and provide recommendations to improve the quality of cost-effectiveness analyses. The need to deliver health care efficiently and the importance of using analytic techniques to understand the clinical and economic consequences of strategies to improve health have increased in recent years.
Since publication of the report by the Panel on Cost-Effectiveness in Health and Medicine in 1996, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have experimented with its application. 16 Department of Family Medicine and Community Health, Miller School of Medicine, University of Miami, Miami, Florida.15 Patient-Centered Outcomes Research Institute, Washington, DC.14 Department of Economics and Institute for Health, Rutgers University, New Brunswick, New Jersey.13 Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, Rhode Island.12 Centre for Health Economics, University of York, York, England.Chan School of Public Health, Boston, Massachusetts. 11 Department of Global Health and Population, Harvard T.10 Child Health Evaluation and Research Unit, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor14Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor.9 VA Palo Alto Health Care System, Palo Alto, California12Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford University, Stanford, California.8 Departments of Medicine and Economics, Harris School of Public Policy Studies, and Center for Health and the Social Sciences, University of Chicago, Chicago, Illinois.7 Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis.6 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada7Toronto Health Economics and Technology Assessment Collaborative, Toronto General Research Institute, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada8Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.5 Department of Economics, McMaster University, Hamilton, Ontario, Canada.4 Division of Medical Ethics, Social Medicine, Harvard Medical School, Boston, Massachusetts.3 Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, and Departments of Health Services and Economics, University of Washington, Seattle.2 Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.1 Duke Clinical Research Institute, Duke University, Durham, North Carolina.